

# Orthofix Reports Second Quarter 2022 Results

8/5/2022

- Net sales of \$118.1 million, a decrease of 3% on a reported basis and flat on a constant currency basis over prior year
- Global Orthopedics net sales growth of 11% on a constant currency basis driven by new products and channel investments
- GAAP EPS of \$0.12 and adjusted EPS of \$0.08
- Executed partnership with CGBio to commercialize Novosis™ rhBMP-2 growth factor in the U.S. and Canada
- Limited launch of Virtuos™ Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute
- Full year revenue guidance of \$455 to \$465, which represents flat to 2% growth on a constant currency basis over prior year

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2022. Net sales were \$118.1 million, earnings per share ("EPS") was \$0.12, and adjusted EPS was \$0.08.

"We're pleased with our execution in the second quarter, which was led by double digit growth in our global orthopedic business as well as early commercial traction of new spine products. In addition, we made significant progress on our innovation initiatives, highlighted by the successful launches of the AccelStim™ Bone Healing Therapy and Virtuos Lyograft, as well as our recent partnerships with LimaCorporate and CGBio," said Orthofix President and Chief Executive Officer Jon Serbousek. "We had solid operational execution, despite the challenges that macro headwinds continue to present, including continued hospital staffing shortages, complex spine procedure softness, and patients deferring care due to economic pressures. In addition, currency fluctuations during the quarter dampened reported revenue results."

Continued Serbousek, "We remain incredibly bullish on the long-term opportunity here at Orthofix. While the macro environment is causing near-term volatility, we are fully committed to driving accelerated topline growth in the high single digits and continuing to execute towards increasing profitability. With the strength of our balance sheet as well as organic and inorganic investments made throughout the organization, we will work to continue to drive growth over the near term from key new product launches and channel expansion."

## Financial Results Overview

The following table provides net sales by major product category by reporting segment:

Three Months Ended June 30,				
(Unaudited, U.S. Dollars, in thousands)	2022	2021	Change	Constant Currency Change
Bone Growth Therapies	\$ 47,765	\$ 49,706	(3.9%)	(3.9%)
Spinal Implants	28,222	30,092	(6.2%)	(5.4%)
Biologics	14,795	14,852	(0.4%)	(0.4%)
Global Spine	90,782	94,650	(4.1%)	(3.8%)
Global Orthopedics	27,288	26,744	2.0%	11.4%
Net sales	\$ 118,070	\$ 121,394	(2.7%)	(0.5%)

Gross profit decreased \$7.5 million to \$86.5 million. Gross margin decreased to 73.2% compared to 77.4% in the prior year period.

Net income was \$2.5 million, or \$0.12 per share, compared to net income of \$2.4 million, or \$0.12 per share in the prior year period. Adjusted net income was \$1.5 million, or \$0.08 per share, compared to adjusted net income of \$6.3 million, or \$0.32 per share in the prior year period.

EBITDA was \$10.0 million, compared to \$12.8 million in the prior year period. Adjusted EBITDA was \$11.4 million, or 9.7% of net sales, compared to \$18.4 million, or 15.1% of net sales, in the prior year period.

### Liquidity

As of June 30, 2022, cash and cash equivalents totaled \$59.5 million, compared to \$87.8 million as of December 31, 2021. As of June 30, 2022, the Company had no borrowings under its five year \$300 million secured revolving credit facility. Cash flow from operations decreased \$12.9 million to \$(12.6) million, while free cash flow decreased \$14.8 million to \$(24.3) million.

## CGBio Exclusive Recombinant Bone Growth Protein Partnership

On August 2, 2022, we announced our new long-term strategic license and distribution agreement with CGBio, a developer of innovative, synthetic bone grafts currently approved and commercially available in South Korea, Southeast Asia, Mexico, and India. The agreement grants us the exclusive right to conduct pre-clinical and clinical studies, commercialize, promote, market, and sell the Novosis (rhBMP-2) recombinant bone growth protein in the U.S. and Canada. Novosis is a novel composite bone graft material that is flowable and provides moldable handling characteristics that are unique compared to what is currently on the market in the U.S. and Canada and represents the next evolution of bone growth factor technology.

## Business Outlook

As of the date hereof, the Company expects the following net sales results for the year ended December 31, 2022. These expectations are based on the current foreign currency exchange rates and do not include any additional exchange rate changes that may occur this year.

	Current 2022 Outlook	Previous 2022 Outlook
(Unaudited, U.S. Dollars, in millions, except per share data)	Range	Range
Full year net sales	\$455 - \$465	\$475 - \$490
Full year net sales growth rates – reported	(2%) - 0%	2% - 5%
Full year net sales growth rates – constant currency	0% - 2%	4% - 7%
Full year adjusted EBITDA	\$53 - \$57	\$56 - \$61
Full year adjusted EBITDA as percentage of net sales <sup>1</sup>	12%	12% - 13%
Full year adjusted EPS	\$0.45-\$0.55	\$0.58-\$0.73

<sup>1</sup> Calculated using the midpoint of estimated full year net sales

The Company is not able to provide expectations of operating income or GAAP EPS, the closest comparable U.S. GAAP measures to Adjusted EBITDA and Adjusted EPS, respectively (each of which are non-GAAP measures), on a forward-looking basis because the Company is unable to predict without unreasonable efforts the ultimate outcome of matters (including legal proceedings, acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded from the applicable non-GAAP measure, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company's results computed in accordance with U.S. GAAP.

## Conference Call

Orthofix will host a conference call today at 8:30 AM Eastern time to discuss the Company's financial results for the second quarter of 2022. Interested parties may access the conference call by dialing (844) 200-6205 in the U.S. and Canada, and (929) 526-1599 all other locations, and referencing the access code 135199. A replay of the call will be available for three weeks by dialing (866) 813-9403 in the U.S. and Canada, and (929) 458-6194 in all other locations, and entering the access code 312854. A webcast of the conference call may be accessed at [ir.Orthofix.com](http://ir.Orthofix.com).

## About Orthofix

Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The Company's mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix's spine and orthopedics products are distributed in

more than 60 countries via the Company's sales representatives and distributors. For more information, please visit [www.orthofix.com](http://www.orthofix.com).

## Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”), and in Part II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Factors that could cause or contribute to such differences may include, but are not limited to, (i) risks relating to the effects of the COVID-19 pandemic on our business, (ii) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (iii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iv) development and acceptance of new products or product enhancements, (v) clinical and statistical verification of the benefits achieved via the use of our products, (vi) our ability to adequately manage inventory, (vii) our ability to recruit and retain management and key personnel, (viii) global economic instability and potential supply chain disruption caused by Russia’s unlawful invasion of Ukraine and resulting sanctions, and (ix) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). To the extent that the COVID-19 pandemic continues to adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in Part I, Item 1A under the heading Risk Factors in our 2021 Form 10-K, such as our ability to generate sufficient cash flows to run our business and our ability to protect our information technology networks and infrastructure from unauthorized access, misuse, malware, phishing and other events that could have a security impact as a result of our remote working environment or otherwise. As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.

This list of risks, uncertainties, and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at [www.sec.gov](http://www.sec.gov). Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-

looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

ORTHOFIX MEDICAL INC.  
Condensed Consolidated Statements of Operations

	Three Months Ended June 30,		Six Months Ended June 30,	
(U.S. Dollars, in thousands, except share and per share data)	2022	2021	2022	2021
	(Unaudited)		(Unaudited)	
Net sales	\$ 118,070	\$ 121,394	\$ 224,488	\$ 226,987
Cost of sales	31,600	27,439	59,918	53,353
Gross profit	86,470	93,955	164,570	173,634
Sales and marketing	59,888	57,338	114,025	108,123
General and administrative	15,846	18,335	35,174	34,779
Research and development	12,758	13,121	23,970	24,018
Acquisition-related amortization and remeasurement	(8,663)	894	(12,162)	5,363
Operating income	6,641	4,267	3,563	1,351
Interest expense, net	(407)	(550)	(782)	(967)
Other income (expense), net	(3,192)	951	(4,128)	(1,739)
Income (loss) before income taxes	3,042	4,668	(1,347)	(1,355)
Income tax expense	(553)	(2,248)	(624)	(2,041)
Net income (loss)	\$ 2,489	\$ 2,420	\$ (1,971)	\$ (3,396)
Net income (loss) per common share:				
Basic	\$ 0.12	\$ 0.12	\$ (0.10)	\$ (0.17)
Diluted	0.12	0.12	(0.10)	(0.17)
Weighted average number of common shares (in millions):				
Basic	20.0	19.7	20.0	19.6
Diluted	20.1	19.9	20.0	19.6

ORTHOFIX MEDICAL INC.  
Condensed Consolidated Balance Sheets

(U.S. Dollars, in thousands, except par value data)	June 30, 2022	December 31, 2021
	(Unaudited)	
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 59,536	\$ 87,847
Accounts receivable, net of allowances of \$5,589 and \$4,944, respectively	77,069	78,560
Inventories	97,171	82,974
Prepaid expenses and other current assets	21,416	20,141
Total current assets	255,192	269,522
Property, plant, and equipment, net	58,676	59,252
Intangible assets, net	50,634	52,666
Goodwill	71,317	71,317
Deferred income taxes	1,454	1,771
Other long-term assets	24,383	22,095
Total assets	\$ 461,656	\$ 476,623
<b>Liabilities and shareholders' equity</b>		
Current liabilities		
Accounts payable	\$ 32,322	\$ 26,459
Current portion of finance lease liability	624	2,590
Other current liabilities	48,151	76,781
Total current liabilities	81,097	105,830
Long-term portion of finance lease liability	19,571	19,890
Other long-term liabilities	19,042	13,969
Total liabilities	119,710	139,689

Contingencies		
Shareholders' equity		
Common shares \$0.10 par value; 50,000 shares authorized; 20,000 and 19,837 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	2,000	1,983
Additional paid-in capital	323,738	313,951
Retained earnings	19,029	21,000
Accumulated other comprehensive loss	(2,821)	—
<b>Total shareholders' equity</b>	<b>341,946</b>	<b>336,934</b>
<b>Total liabilities and shareholders' equity</b>	<b>\$ 461,656</b>	<b>\$ 476,623</b>

## ORTHOFIX MEDICAL INC.

### Non-GAAP Financial Measures

The following tables present reconciliations of operating income (loss), net income (loss), EPS, and net cash from operating activities, in each case calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), to, as applicable, non-GAAP financial measures, referred to as "EBITDA," "Adjusted EBITDA," "Adjusted net income (loss)," "Adjusted EPS," and "Free cash flow" that exclude items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measure(s) shown in the table. A more detailed explanation of the items excluded from these non-GAAP financial measures, as well as why management believes the non-GAAP financial measures are useful to them, is included following the reconciliations. The non-GAAP adjusted results shown below and within this press release, which exclude the items specified in the reconciliation tables below, should not be construed as a substitute for, or a better indicator of, the Company's performance than the Company's GAAP results.

#### EBITDA and Adjusted EBITDA

Three Months Ended June 30, 2022				
(Unaudited, U.S. Dollars, in thousands)	Total Orthofix	Global Spine	Global Orthopedics	Corporate
Operating income (loss)	\$ 6,641	\$ 17,551	\$ (2,290)	\$ (8,620)
Other income (expense), net	(3,192)	(810)	(1,736)	(646)
Depreciation and amortization	4,461	2,137	1,441	883
Amortization of acquired intangibles	2,051	1,888	163	—
<b>EBITDA</b>	<b>\$ 9,961</b>	<b>\$ 20,766</b>	<b>\$ (2,422)</b>	<b>\$ (8,383)</b>
Share-based compensation	4,449	1,957	252	2,240
Foreign exchange impact	2,991	664	1,801	526
Strategic investments	1,824	39	270	1,515
Acquisition-related fair value adjustments	(10,714)	(10,714)	—	—
Loss on investment securities	123	—	—	123
Legal judgments/settlements	148	110	39	(1)
Succession and transition charges	68	44	7	17
Medical device regulation	2,257	1,431	830	(4)
Business interruption - COVID-19	316	313	3	—
<b>Adjusted EBITDA</b>	<b>\$ 11,423</b>	<b>\$ 14,610</b>	<b>\$ 780</b>	<b>\$ (3,967)</b>
As a % of net sales	9.7%	12.4%	0.7%	-3.4%

Six Months Ended June 30, 2022

(Unaudited, U.S. Dollars, in thousands)	Total Orthofix	Global Spine	Global Orthopedics	Corporate
Operating income (loss)	\$ 3,563	\$ 28,918	\$ (6,562)	\$ (18,793)
Other income (expense), net	(4,128)	(735)	(2,477)	(916)
Depreciation and amortization	9,752	4,759	2,962	2,031
Amortization of acquired intangibles	4,276	3,717	559	—
EBITDA	\$ 13,463	\$ 36,659	\$ (5,518)	\$ (17,678)
Share-based compensation	8,697	3,411	853	4,433
Foreign exchange impact	4,233	1,037	2,512	684
Strategic investments	2,794	102	415	2,277
Acquisition-related fair value adjustments	(16,214)	(16,214)	—	—
Loss on investment securities	188	—	—	188
Legal judgments/settlements	341	116	223	2
Succession and transition charges	78	54	7	17
Medical device regulation	4,293	2,837	1,466	(10)
Business interruption - COVID-19	659	641	18	—
Adjusted EBITDA	\$ 18,532	\$ 28,643	\$ (24)	\$ (10,087)
As a % of net sales	8.3%	12.8%	0.0%	-4.5%

Three Months Ended June 30, 2021

(Unaudited, U.S. Dollars, in thousands)	Total Orthofix	Global Spine	Global Orthopedics	Corporate
Operating income (loss)	\$ 4,267	\$ 14,212	\$ (1,037)	\$ (8,908)
Other income (expense), net	951	398	645	(92)
Depreciation and amortization	5,324	2,638	1,716	970
Amortization of acquired intangibles	2,235	1,784	451	—
EBITDA	\$ 12,777	\$ 19,032	\$ 1,775	\$ (8,030)
Share-based compensation	3,900	1,618	606	1,676
Foreign exchange impact	(1,061)	(378)	(775)	92
Strategic investments	1,150	152	634	364
Acquisition-related fair value adjustments	(1,089)	(714)	—	(375)
Legal judgments/settlements	61	1	59	1
Succession and transition charges	613	392	62	159
Medical device regulation	1,987	602	559	826
Business interruption - COVID-19	26	4	10	12
Adjusted EBITDA	\$ 18,364	\$ 20,709	\$ 2,930	\$ (5,275)
As a % of net sales	15.1%	17.1%	2.4%	-4.3%

Six Months Ended June 30, 2021

(Unaudited, U.S. Dollars, in thousands)	Total Orthofix	Global Spine	Global Orthopedics	Corporate
Operating income (loss)	\$ 1,351	\$ 22,324	\$ (3,899)	\$ (17,074)
Other income (expense), net	(1,739)	(218)	(793)	(728)
Depreciation and amortization	10,532	5,252	3,337	1,943
Amortization of acquired intangibles	4,470	3,569	901	—
EBITDA	\$ 14,614	\$ 30,927	\$ (454)	\$ (15,859)
Share-based compensation	7,621	3,126	1,132	3,363
Foreign exchange impact	1,601	246	626	729
Strategic investments	2,561	152	1,734	675
Acquisition-related fair value adjustments	1,475	1,850	—	(375)
Legal judgments/settlements	2	(50)	105	(53)
Succession and transition charges	643	422	62	159
Medical device regulation	3,811	1,105	1,066	1,640
Business interruption - COVID-19	47	6	16	25

Adjusted EBITDA	\$ 32,375	\$ 37,784	\$ 4,287	\$ (9,696)
As a % of net sales	14.3%	16.6%	1.9%	-4.3%

## Adjusted Net Income (Loss)

(Unaudited, U.S. Dollars, in thousands)	Three Months Ended June 30,		Six Months Ended June 30,	
	2022	2021	2022	2021
Net income (loss)	\$ 2,489	\$ 2,420	\$ (1,971)	\$ (3,396)
Foreign exchange impact	2,991	(1,061)	4,233	1,601
Strategic investments	1,817	1,181	2,782	2,633
Acquisition-related fair value adjustments	(10,714)	(1,089)	(16,214)	1,475
Amortization of acquired intangibles	2,051	2,242	4,282	4,481
Loss on investment securities	123	—	188	—
Legal judgments/settlements	148	61	341	2
Succession and transition charges	68	613	78	643
Medical device regulation	2,260	1,987	4,296	3,811
Business interruption - COVID-19	318	28	663	51
Long-term income tax rate adjustment	(37)	(82)	819	(1,562)
Adjusted net income (loss)	\$ 1,514	\$ 6,300	\$ (503)	\$ 9,739

## Adjusted EPS

(Unaudited, per diluted share)	Three Months Ended June 30,		Six Months Ended June 30,	
	2022	2021	2022	2021
EPS	\$ 0.12	\$ 0.12	\$ (0.10)	\$ (0.17)
Foreign exchange impact	0.15	(0.05)	0.21	0.08
Strategic investments	0.09	0.06	0.14	0.13
Acquisition-related fair value adjustments	(0.53)	(0.05)	(0.81)	0.08
Amortization of acquired intangibles	0.10	0.11	0.21	0.22
Loss on investment securities	0.01	—	0.01	—
Legal judgments/settlements	0.01	—	0.02	—
Succession and transition charges	—	0.03	—	0.03
Medical device regulation	0.11	0.10	0.22	0.19
Business interruption - COVID-19	0.02	—	0.03	—
Long-term income tax rate adjustment	—	—	0.04	(0.07)
Adjusted EPS	\$ 0.08	\$ 0.32	\$ (0.03)	\$ 0.49
Weighted average number of diluted common shares (treasury stock method, in millions)	20.1	20.0	20.0	19.9

## Cash Flow and Free Cash Flow

(Unaudited, U.S. Dollars, in thousands)	Six Months Ended June 30,	
	2022	2021
Net cash from operating activities	\$ (12,622)	\$ 264
Net cash from investing activities	(13,161)	(9,792)
Net cash from financing activities	(1,324)	(6,528)
Effect of exchange rate changes on cash	(1,204)	(243)
Net change in cash and cash equivalents	\$ (28,311)	\$ (16,299)



(Unaudited, U.S. Dollars, in thousands)	Six Months Ended June 30,	
	2022	2021
Net cash from operating activities	\$ (12,622)	\$ 264
Capital expenditures	(11,703)	(9,792)
Free cash flow	\$ (24,325)	\$ (9,528)

## Constant Currency

Constant currency is a non-GAAP measure, which we calculate by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

## EBITDA

EBITDA is a non-GAAP financial measure, which we calculate by adding interest income (expense), net; income tax expense (benefit); and depreciation and amortization to net income. EBITDA provides management with additional insight to its results of operations. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing our business.

## Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted EPS

These non-GAAP financial measures provide management with additional insight to its results of operations and reflect the exclusion of the following items:

- Share-based compensation expense – costs related to our share-based compensation plans, which include stock options, restricted stock, performance-based or market-based restricted stock, and our stock purchase plan; see the share-based compensation footnote in our Form 10-Q for the quarter ended June 30, 2022 for an allocation of these costs by consolidated statement of operations line item; note that certain share-based compensation costs are instead included within medical device regulation for 2021 and 2022
- Foreign exchange impact – gains and losses related to foreign currency transactions, which are recorded as other income (expense), net
- Strategic investments – costs related to our strategic investments, such as due diligence and integration costs, which are primarily recorded as general and administrative expenses
- Acquisition-related fair value adjustments – comprised of (i) gains and losses related to remeasurement of contingent consideration to fair value, which are recorded as operating expenses and (ii) recognized costs related to acquired in-process research and development assets, which were expensed immediately
- Amortization of acquired intangibles – amortization of intangible assets acquired in business combinations or asset acquisitions, including items such as developed technologies, customer relationships, trade names,

manufacturing agreements, and other intangible assets, which are recorded in cost of sales or operating expenses

- Loss on investment securities – net gains or losses recognized (realized or unrealized) within other income (expense), net relating to certain of our investments
- Legal judgments/settlements – adverse or favorable legal judgments or negotiated legal settlements, which are recorded as general and administrative expenses
- Succession and transition charges – costs related to the transition of certain named executive officers and certain targeted restructuring costs, including any cessation and onboarding amounts, accelerated share-based compensation expense, consulting services, and other related expenses, which are primarily recorded as general and administrative expenses
- Medical device regulation – incremental costs incurred (i) to establish initial compliance with the regulations set forth by the European Union Medical Device Regulation (“MDR”) and the U.S. Food and Drug Administration related to our currently-approved medical devices, which are recorded primarily as research and development expenses, and (ii) related to rationalization of certain product lines that we do not expect to continue to market subsequent to the effective date of these regulations, which are recorded primarily as costs of sales
- Business interruption – COVID-19 – gains and losses related to the realized effects the COVID-19 pandemic has had on our business operations, which consist primarily of (i) certain legislative relief received as a result of the COVID-19 pandemic, (ii) costs associated with the redesign of certain products in response to supply chain disruption, and (iii) incremental costs incurred to enhance the safety and sanitation of our facilities
- Long-term income tax rate adjustment – reflects management’s expectation of a long-term normalized effective tax rate of 27% for 2021 and 28% for the fiscal year 2022 results and outlook, which is based on current tax law and current expected adjusted income; actual reported tax expense will ultimately be based on GAAP earnings and may differ from the expected long-term normalized effective tax rate due to a variety of factors, including the resolutions of issues arising from tax audits with various tax authorities, the ability to realize deferred tax assets, and the tax impact of certain reconciling items that are excluded in determining Adjusted Net Income and Adjusted EPS

## Free Cash Flow

Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow from operating activities. Free cash flow is an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow to measure progress on its capital efficiency and cash flow initiatives.

## Usefulness and Limitations of Non-GAAP Financial Measures

Management uses non-GAAP measures to evaluate performance period-over-period, analyze the underlying trends in our business, assess performance relative to competitors, and establish operational goals and forecasts that are

used in allocating resources. Management uses these non-GAAP measures as the basis for evaluating the ability of the underlying operations to generate cash. In addition, management uses these non-GAAP measures to further its understanding of the performance of our business units.

#### Material Limitations Associated with the Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost and can have a material effect on cash flows. Similarly, certain non-cash expenses, such as share-based compensation, do not directly impact cash flows, but are part of total compensation costs accounted for under GAAP.

#### Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

We compensate for the limitations of our non-GAAP financial measures by relying upon GAAP results to gain a complete picture of our performance. The GAAP results provide management with the ability to further understand our performance based on a defined set of criteria. Management believes that the non-GAAP measures reflect the underlying operating results of our businesses and provide an important measure of our overall performance. We provide detailed reconciliations of the non-GAAP financial measures to the most directly comparable GAAP measures above and encourage investors to review these reconciliations.

#### Usefulness of Non-GAAP Financial Measures to Investors

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. Management believes it is important to provide investors with the same non-GAAP metrics it uses to supplement information regarding the performance and underlying trends of our business operations in order to facilitate comparisons to our historical operating results and internally evaluate the effectiveness of our operating strategies. We believe that disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20220805005043/en/>

Orthofix Medical Inc.

Alexa Huerta

P: 214-937-3190

E: [alexahuerta@orthofix.com](mailto:alexahuerta@orthofix.com)

Source: Orthofix Medical Inc.